Table 2.
Cytogenetic analysis according to treatment arm
| 600 mg bid day 1–21 (n=80) | 600 mg bid d 1–7, 15–21 (n=85) | 300 mg bid day 1–21 (n=82) | 300 mg bid d 1–7, 15–21 (n=84) | ||
|---|---|---|---|---|---|
| Evaluable1 | 71% | 83% | 68% | 74% | |
| Normal karyotype | 35% | 29% | 23% | 28% | |
| Risk group2 | |||||
| Intermediate | 54% | 37% | 35% | 38% | |
| Unfavorable3 | 42% | 54% | 58% | 47% | |
| Karyotype complexity | |||||
| ≥ 3 | 31% | 37% | 38% | 34% | |
| ≥ 5 | 15% | 31% | 31% | 25% |
1
Data from 167 SWOG patients; 124 with evaluable cytogenetic analysis
2
Only 3 patients had CBF translocations; not (15;17)
3
−5/5q- in 34%, −7/7q- in 23%